# Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis

> **NCT04874714** · PHASE3 · TERMINATED · sponsor: **Inmunotek S.L.** · enrollment: 18 (actual)

## Conditions studied

- Allergic Rhinoconjunctivitis
- Perennial Allergic Rhinitis
- House Dust Mite Allergy
- Pollen Allergy

## Interventions

- **BIOLOGICAL:** MM09-MG01(30.000-30.000)
- **BIOLOGICAL:** MG01(30.000)
- **BIOLOGICAL:** MM09(30.000)
- **BIOLOGICAL:** Placebo subcutaneous

## Key facts

- **NCT ID:** NCT04874714
- **Lead sponsor:** Inmunotek S.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-30
- **Primary completion:** 2023-10-09
- **Final completion:** 2023-10-09
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Due to the low recruitment rate since the start of the trial
- **Last updated:** 2023-12-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04874714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04874714, "Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04874714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*